ACTICOAT*

• Proprietary silver technology
• Broad-spectrum antimicrobial activity against over 150 organisms including 200 strains of MRSA and five organisms that carry the NDM-1 enzyme (in vitro)
• Three day wear time
• Provides bactericidal activity within 30 minutes
• May help reduce the risk of infection
• Can be used on extensive body surface area wounds and over debrided wounds
• Low-adherent
• Can be cut to size

ACTICOAT* is indicated for use on partial- and full-thickness wounds, such as pressure ulcers, diabetic ulcers, venous ulcers, surgical sites, donor sites, grafts/dermal substitutes and first- and second-degree burns.

Do not use on patients with a known sensitivity to silver. During MRI (Magnetic Resonance Imaging) examination, remove from area within the anatomical field being imaged.
Prior to administering radiation therapy, remove ACTICOAT*. A new dressing can be applied following treatment.

Do not use if product color is not uniform.
For external use only.
ACTICOAT* is not compatible with oil-based products, such as petrolatum.
Avoid contact with electrodes or conductive gels during electronic measurements (e.g., EEG and ECG).
ACTICOAT* should only be used on premature infants (less than 37 weeks gestation) when the clinical benefit outweighs potential risks. No clinical data is available on this age group and only limited data is available for use on neonates.
ACTICOAT* is not intended to provide sole treatment for infected wounds.
ACTICOAT* may be used on infected wounds which are being managed per local clinical protocol.

May cause transient discoloring of surrounding skin.

Avoid exposure to temperatures above 120°F (50°C). Protect from light.